BAD: A Protein Implicated in Cell Survival and Disease (G572)

Target Name: BAD

NCBI ID: G572

Content of Review Report on BAD Target / Biomarker

BAD

BAD: A Protein Implicated in Cell Survival and Disease

BAD (Bcl-2 associated agonist of cell death) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, liver, and heart. It is a key regulator of cell survival and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of BAD is to prevent cells from undergoing programmed cell death, also known as apoptosis. Apoptosis is a natural process that helps the body eliminate damaged or dysfunctional cells, but it can also be caused by factors such as exposure to toxins or radiation. When cells undergo apoptosis, they are typically programmed to die, but BAD can help prevent this from happening.

In addition to its role in preventing apoptosis, BAD is also involved in a number of other cellular processes that are important for cell survival. For example, BAD has been shown to play a role in the regulation of cell proliferation, cell migration, and the formation of tissues. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of cancer.

Despite its involvement in so many important cellular processes, BAD is not well understood. In fact, the precise function of this protein is not yet fully understood, and much of its biology remains unexplored. However, research into BAD is ongoing, and there is a growing interest in its potential as a drug target or biomarker.

One of the potential reasons for the lack of understanding of BAD is its complex structure. BAD is a protein that is composed of multiple domains, including an N-terminus, a T-terminus, and a middle domain that is responsible for much of its function. While the precise function of the middle domain is not yet fully understood, it is thought to be involved in the regulation of cell survival and in the regulation of cellular processes such as inflammation.

Another reason for the lack of understanding of BAD is its role in a number of diseases. BAD is often expressed at higher levels in tissues that are affected by diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that BAD may be a useful biomarker or drug target in these diseases. For example, studies have shown that BAD is often expressed at higher levels in the brains of individuals with Alzheimer's disease, and that it may be a useful target for drug development in this disease.

In addition to its potential as a drug target or biomarker, BAD is also of interest as a potential therapeutic agent. For example, studies have shown that BAD can be expressed at higher levels in a variety of cancer cells, and that it may be a useful target for cancer therapy. In addition, BAD has been shown to have a number of potential therapeutic effects in its own right, such as its ability to prevent apoptosis and its involvement in the regulation of cell proliferation and migration.

Overall, BAD is a protein that is of great interest to researchers due to its complex structure and its involvement in a number of important cellular processes. While much of its biology remains unexplored, research into BAD is ongoing, and there is a growing interest in its potential as a drug target or biomarker. As research continues, it is likely that the full potential of BAD will be revealed and its applications will continue to grow.

Protein Name: BCL2 Associated Agonist Of Cell Death

Functions: Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways

The "BAD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets